Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells

Area of Science:

• Immunology
• Oncology
• Cancer Metastasis

Background:

• Carcinoma metastasis is driven by circulating tumor cells (CTCs).
• Single immune checkpoint inhibitors are insufficient for blocking CTC-induced metastasis.
• CD47 (don't eat me) and CD274 (don't find me) are key immune checkpoints on CTCs.

Purpose of the Study:

• To investigate the efficacy of simultaneously blocking CD47 and CD274 checkpoints on CTCs.
• To compare dual-blockade therapy with single-target therapies against CTC-induced metastasis.

Main Methods:

• In vitro flow cytometry to assess CD47 and CD274 overexpression on mouse tumor cell lines.
• Antibody-based blockade of CD47 and CD274 on tumor cells.
• In vivo studies using a 4T1 tumor mouse model to evaluate therapeutic efficacy.

Main Results:

• CD47 and CD274 were overexpressed on tested mouse tumor cell lines.
• Antibodies effectively blocked CD47 and CD274 expression on tumor cells.
• Simultaneous blockade of CD47 and CD274 significantly inhibited tumor growth and CTC metastasis more than single-target therapies or controls.

Conclusions:

• Dual targeting of CD47 and CD274 immune checkpoints on CTCs shows enhanced therapeutic potential.
• Combined CD47 and CD274 blockade represents a promising immunotherapeutic strategy for inhibiting cancer metastasis.